PI3K-IN-16

CAS No. 1895876-81-9

PI3K-IN-16( —— )

Catalog No. M12977 CAS No. 1895876-81-9

PI3K-IN-16 is a potent and selective, orally bioavailable PI3Kβ and PI3Kδ inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    PI3K-IN-16
  • Note
    Research use only, not for human use.
  • Brief Description
    PI3K-IN-16 is a potent and selective, orally bioavailable PI3Kβ and PI3Kδ inhibitor.
  • Description
    PI3K-IN-16 is a potent and selective, orally bioavailable PI3Kβ and PI3Kδ inhibitor with cell IC50 of 12 nM (in PTEN null MDA-MB-468 cell) and 47 nM (in Jeko-1 B-cell), respectively; exhibits no significant activity on PI3Kα; shows profound pharmacodynamic modulation of AKT phosphorylation, excellent tumour growth inhibition in a mouse PTEN-deficient PC3 prostate tumour xenograft.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    PI3K
  • Recptor
    PI3K
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1895876-81-9
  • Formula Weight
    467.497
  • Molecular Formula
    C25H26FN3O5
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    8-((8-fluoro-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)methyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Barlaam B, et al. Bioorg Med Chem Lett. 2016 May 1;26(9):2318-23.
molnova catalog
related products
  • GNE-493

    A potent, selective dual pan-PI3K/mTOR inhibitor with IC50 of 3.4/12/16/16/32 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ/mTOR.

  • NSC5844

    NSC5844 (RE640) is a bisquinoline compound with C-C chemokine receptor type 1 (CCR1)-agonistic activities.

  • Splitomicin

    Splitomicin (IC50 of 60 μM), a specific inhibitor of NAD(+)-dependent histone deacetylase Sir2p, displays a high activity in a cell-based assay.